Products for Research Use Only
RegisterLogin

Tepotinib

CAT: 0931-T6121-08Size: 100 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0931-T6121-08Size:100 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
CAS Number
1100598-32-0
Target
C-Met/HGFR, Autophagy, TAM Receptor, Trk receptor
Related Pathways
Tyrosine Kinase/Adaptors, Autophagy
Purity
0.9991
Bioactivity
Tepotinib (EMD-1214063) is a c-MET tyrosine kinase inhibitor (IC50=3 nM) that is selective, orally active, and ATP-competitive. Tepotinib has antitumor effect and is used in the treatment of non-small cell lung cancer.
Smiles
CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1
Molecular Formula
C29H28N6O2
Molecular Weight
492.57
Shipping Conditions
Ice Packs
Storage Temperature
-20°C

Chemical Information

Tepotinib

Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma, gastric cancers, non-small cell lung cancer, and hepatocellular carcinoma. MET is a desirable target in the treatment of certain solid tumors as it appears to play a critical role, both directly and indirectly, in the growth and proliferation of tumors in which it is overexpressed and/or mutated. Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with MET alterations, and was subsequently granted accelerated approval by the US FDA in February 2021, under the brand name Tepmetko, for the treatment of adult patients with metastatic NSCLC and MET exon 14 skipping alterations. It is the first oral MET-targeted tyrosine kinase inhibitor to allow for once-daily dosing, an advantage that may aid in easing the pill burden often associated with chemotherapeutic regimens. In February 2022, tepotinib was approved for use in Europe.

CAS Number1100598-32-0
PubChem CID25171648
IUPAC Name3-[1-[[3-[5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl]phenyl]methyl]-6-oxopyridazin-3-yl]benzonitrile
Molecular FormulaC29H28N6O2
Molecular Weight492.6
XLogP3.4
Topological Polar Surface Area94.7
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count7
Rotatable Bond Count7
Heavy Atom Count37
Formal Charge0
Complexity880
SMILES
CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC=CC(=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N
InChI
InChI=1S/C29H28N6O2/c1-34-12-10-21(11-13-34)20-37-26-17-31-29(32-18-26)25-7-3-5-23(15-25)19-35-28(36)9-8-27(33-35)24-6-2-4-22(14-24)16-30/h2-9,14-15,17-18,21H,10-13,19-20H2,1H3
InChIKey
AHYMHWXQRWRBKT-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of Tepotinib
CAS: 1100598-32-0
CID: 25171648
Formula: C29H28N6O2
MW: 492.6
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight492.6
XLogP33.4
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count7
Rotatable Bond Count7
Exact Mass492.22737416
Monoisotopic Mass492.22737416
Topological Polar Surface Area94.7 Ų
Heavy Atom Count37
Formal Charge0
Complexity880
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Alternative Products

CatalogName
HY-14721-01Tepotinib
HY-14721ATepotinib (hydrochloride)
HY-14721R-01Tepotinib (Standard)
RM-T283002-01Tepotinib Impurity 2
RM-T283007-01Tepotinib Impurity 7
RM-T283006-01Tepotinib Impurity 6
RM-T283003-01Tepotinib Impurity 3
RM-T283005-01Tepotinib Impurity 5
RM-T283004-01Tepotinib Impurity 4
A11257-100Tepotinib (EMD-1214063) 100mg

Popular Products